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1Regular exercise training places demands on the heart that may lead to cardiac remodeling. The rare but prominent 
cases of sudden cardiac death in elite athletes have underlined 
the importance of understanding the adaptation underlying ath-
lete’s heart (AH).1 Gaining insights into the remodeling pro-
cess is important to understand the nature of adaptation and to 
develop tools that distinguish AH from cardiomyopathic change, 
particularly those of hypertrophic cardiomyopathy (HCM).
See Editorial by Graham-Brown and McCann 
See Clinical Perspective
Cardiovascular magnetic resonance (CMR) imaging is 
particularly well suited to investigate changes of structure and 
function in athletic cardiac remodeling because of its multipa-
rametric capabilities, high spatial resolution, and lack of ion-
izing radiation. The excellent reproducibility of the method 
means that anatomic change can be quantified with greater 
confidence and smaller sample size than with other methods.2,3 
The emerging CMR technique of extracellular volume (ECV) 
quantification allows the relative volumes of the extracellular 
and intracellular myocardial compartments to be quantified. 
This method has been used to quantify extracellular expansion 
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(higher ECV) secondary to interstitial fibrosis in cardiomy-
opathy4 and conversely greater myocyte volume (lower ECV) 
in pathologies such as Anderson–Fabry disease.5,6
In this study, we sought to characterize cardiac adaptation 
in male athletes using CMR to gain insights into the mecha-
nisms underlying athletic remodeling. We hypothesized that 
in athletes, left ventricular (LV) hypertrophy occurs secondary 
to an increase in myocardial cellular mass rather than ECV 
and that changes become increasingly prominent with increas-
ing aerobic capacity (V̇O2max).
Methods
Male athletic participants aged between 20 and 45 years were ap-
proached via athletic societies and associations. Recruitment was 
open to athletes competing at regional, national, and international 
level. Subjects were eligible for inclusion if they took part in regular 
competition and trained for a minimum of 6 hours per week.
In addition, untrained males who exercised <3 hours per week 
were recruited from the study institution as a control group. Untrained 
individuals did not undertake regular athletic training. Subjects were 
not eligible if they had contraindications to CMR, hypertension (sys-
tolic blood pressure >140 mm Hg), or systemic medical illness. All 
athletes underwent a CMR study before a maximal exercise test, per-
formed on the same day when logistically possible.
The study was conducted in accordance with the Declaration of 
Helsinki and was approved by the local ethics committee (Research 
and Ethics Committee reference: 14/YH/0126). All subjects gave in-
formed written consent.
Cardiac Magnetic Resonance Protocol
The CMR study was performed at rest and before exercise testing in 
athletes. All studies were performed on a 3-Tesla Achieva TX system 
equipped with a 32-channel cardiac phased array receiver coil and 
multitransmit technology (Philips Healthcare, Best, The Netherlands). 
The cardiac long and short axes were determined using standard scout 
views. Mid-LV native (precontrast) T1 maps were generated using 
a previously described MOLLI sequence7 planned using the 3 of 5 
method8 briefly comprising: ECG triggered 5b(3s)3b MOLLI, flip 
angle 35°, voxel size of 1.98×1.98×10 mm3. LV mass and volumes 
were obtained from cine imaging covering the entire LV in the short 
axis: balanced SSFP, voxel size 1.2×1.2×10 mm3, no gap, 50 cardiac 
phases. Right ventricular and atrial volumes were obtained from a 
transaxial stack covering the entire heart: balanced SSFP, voxel size 
1.7×1.5×5 mm3, no interslice gap. 0.15 mmol/kg Gadovist (Bayer 
Schering) was delivered by power injector (Medrad Inc, Warrendale, 
PA) as a single bolus via a venous cannula placed in the antecubital 
fossa, followed by a 20 mL saline flush at 5 mL/s. Late gadolinium en-
hancement (LGE) imaging (inversion recovery-prepared T1-weighted 
gradient echo, inversion time according to Look-Locker scout, TR/TE/
flip angle 3.7 ms/2.0 ms/25°, acquired spatial resolution 1.54×1.75×10 
mm) was performed to image the entire LV 7 to 10 minutes after con-
trast administration. Post-contrast T1 maps were acquired using the 
same MOLLI scheme 10 minutes after contrast administration.
Image Analysis
All image analysis was performed using cmr42 software (Circle 
Cardiovascular Imaging Inc, Calgary, Alberta, Canada). Volumetric 
and mass analysis was performed in the standard manner from the 
short-axis stack9 (LV) or long-axis cine images10 (right ventricular, 
left and right atria). Ventricular and atrial measurements were indexed 
to body surface area. The presence of focal fibrosis or scar was as-
sessed qualitatively from LGE imaging. T1 values were calculated 
from source images using manual motion correction, with a region of 
interest in the mid-inferoseptum as per Rogers et al.11 Partition coef-
ficient (λ) and ECV were calculated using the formulae:
where R1=1/T1 and Hct is hematocrit.
CMR chamber and tissue values were indexed to body surface 
area and estimated lean body mass (height2.7). Indexed myocyte and 
extracellular mass were calculated using the formulae: indexed myo-
cyte mass=indexed LV mass×(100−%ECV); indexed extracellular 
mass=indexed LV mass×%ECV. (The standard deviation of ECV 
measurement in our center in a cohort of 30 healthy individuals was 
2.8%.) All T1, ECV, volumetric, and mass analyses were performed 
by 2 observers (A. K. McDiarmid and B. Erhayiem) blinded to all 
subject data, including sporting discipline and aerobic capacity.
Exercise Protocol
Participants were instructed to arrive rested (no strenuous exercise in 
the preceding 24 hours) and having abstained from any alcohol (pre-
ceding 24 hours), food, and caffeine (preceding 3 hours) ingestion. To 
determine maximal oxygen uptake (V̇O2max) and ventilatory thresh-
old, participants undertook a ramp-incremental step-exercise test on 
an electronically braked cycle ergometer (Excalibur Sport, Lode BV, 
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Table 1. Subject Characteristics
Untrained 
Individuals (n=15)
All Athletes 
(n=30) P Value
Low Performance 
(n=14)
High Performance 
(n=16) P Value
Age, y 30.3±8.1 31.7±7.7 0.25 35.5±6.5 28.4±7.2 0.40
Weight, kg 77.4±9.9 75.3±7.1 0.42 78.7±5.7 72.3±7.0 0.41
Height, cm 178.0±5.8 181.5±5.0 0.06 182.2±5.2 180.9±4.8 0.96
BMI, kg/m2 24.4±2.5 22.8±1.9 0.02 23.7±1.4 22.1±1.9 0.13
Hematocrit, g/dL 0.46±0.3 0.46±0.03 0.99 0.46±0.03 0.46±0.02 0.14
Systolic 117.3±9.5 120.0±9.0 0.42 120.0±8.7 119.4±10.3 0.93
Diastolic 61.9±10.8 70.3±9.9 0.03 72.0±9.4 67.6±10.7 0.83
Discipline 0.16
  Running 7 3 4
  Cycling 11 3 8
  Triathlon 12 8 4
BMI indicates body mass index.
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Groningen, the Netherlands), which allows for confirmation of VO2max 
in a single test.12 Participants wore a nose clip and breathed through 
a low-dead space, low-resistance mouthpiece which was connected to 
a bidirectional pitot tube flow sensor and gas sample line assembly, 
allowing for breath-by-breath measurement of gas volumes and con-
centrations (O2, Galvanic; CO2 infrared) and subsequent calculation of 
ventilatory and pulmonary gas exchange variables (Cardio2, Medical 
Graphics Corporation, St Paul, MN). Before each test, the pitot tube 
flow sensor was calibrated over a range of flow rates using a 3 L syringe, 
whereas the gas analysers were calibrated using precision gases that 
spanned the inspired and expired physiological range. A 12-lead ECG 
was monitored throughout, and heart rate was measured from the R-R 
interval. The ramp-incremental step-exercise test was preceded by a rest 
period (≈2 minutes) and unloaded cycling (20 W; ≈4 minutes) and con-
tinued until a steady state was attained, after which work rate increased 
as a linear function of time at a rate of 20 to 30 W/min (depending on 
reported training history), with the intention of bringing participants to 
the limit of tolerance in ≈10 to 12 minutes.13 The ramp increment was 
then followed by 5 minutes of active recovery (20 W), after which a step 
exercise (SE) was performed at 95% of the RI work rate peak, with this 
SE also continued to the limit of tolerance. In both RI and SE parts of 
the test, the limit of tolerance was defined as the point at which cycling 
cadence fell below 50 rpm, despite strong verbal encouragement.
Breath-by-breath data were edited using the V̇O2 response to 
eliminate erroneous breaths (occurring outside the local mean 99% 
prediction limits) that were considered unphysiological.14 Anaerobic 
threshold was then estimated using the V-slope method15 and sup-
porting ventilatory and pulmonary gas exchange criteria (ie, the 
fractional end-tidal concentrations of O2 and CO2, and the ventila-
tory equivalents for O2 and CO216). V̇O2peak was identified in both RI 
and SE phases as the highest 12-breath rolling average (highest mean 
V̇O2 over ≈15–20 s).12 Within subjects, the highest 12-breath rolling 
average from RI and SE phases were then compared using unpaired 
t tests, with no difference (P>0.05) between RI and SE V̇O2peak, and 
thus the attainment of V̇O2max was confirmed in each test.17
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics 20.0 
(IBM Corp, Armonk, NY). Subjects were grouped as follows: un-
trained, athletes with V̇O2max <60 mL/kg per min (low-performance 
group), and athletes with V̇O2max >60 mL/kg per min (high-perfor-
mance group). Unless otherwise stated, the results are presented as 
mean±standard deviation (SD). Normality of distribution was de-
termined with Kolmogarov–Smirnov testing. Differences between 
groups were assessed using the Chi-squared test, independent t test, 
or 1-way analysis of variance when appropriate. Post hoc analysis 
was performed with Bonferroni testing. Correlation was assessed 
with Spearman correlation coefficient. Significance for all tests was 
assumed with P<0.05.
Results
Study Participant Demographics and 
Characteristics
Thirty endurance athletes (7 runners, 11 cyclists, and 12 triath-
letes) and 15 untrained sedentary controls were recruited. Ath-
letic and untrained participants were prospectively matched 
for age (31.7±7.7 versus 30.3±8.1 years; P=0.54). Hemato-
crit was not significantly different between groups (0.46±0.3 
versus 0.46±0.3 g/dL; P=0.99), but body mass index was sig-
nificantly lower in athletes (22.8±1.9 versus 24.4±2.5 kg/m2; 
P=0.02). CMR study and maximal exercise testing were sepa-
rated by a median of 0 days (quartile range 1–3). Full study 
participant information may be seen in Table 1.
Table 2. RISE Maximal Exercise Test Results
Low Performance 
(n=14)
High Performance 
(n=16) P Value
Max power, W 377.3±53.8 394.4±58.5 0.42
Resting HR, bpm 54.9±5.2 53.8±7.8 0.66
Peak HR, bpm 180.2±9.6 181.3±11.5 0.80
ΔHR, bpm 116.4±34.5 127.4±8.9 0.23
Ventilatory threshold,  
% of V̇O
2max
59.5±7.6 61.9±6.5 0.36
VO
2max
, mL/kg per min 54.2±4.5 65.5±6.2 <0.001
High- and low-performance groups defined as a V̇O
2max
 of more or less than 60 
mL/kg per min. HR indicates heart rate; and RISE, ramp-incremental step-exercise.
Figure 1. Myocardial remodeling by performance group. A, Cellular mass increases out of proportion to increase in extracellular mass. B, Indexed 
left ventricular end-diastolic volume (LVEDV) and left ventricular (LV) mass increases stepwise as athletic grouping changes (P<0.001 for both).
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Performance Stratification and Cardiopulmonary 
Exercise Testing
Athletes were divided into high- and low-performance groups 
at a threshold V̇O2max of 60 mL/kg per min (n=16 and 14, 
respectively). Mean V̇O2max and anaerobic threshold as a per-
centage of V̇O2max in high-performance and low-performance 
athletes, respectively, were 65.5±6.2 versus 54.2±4.5 mL/kg 
per min (P<0.001) and 61.9±6.5% versus 59.5±7.6% (P=0.36). 
No significant atrial or ventricular ectopy was recorded in the 
exercise or recovery phase of the exercise protocol. None of 
resting, peak, or Δheart rate differed between groups. Maxi-
mal exercise test results are summarized in Table 2.
Myocardial Remodeling
Indexed cellular mass was greater in high-performance athletes 
than in low-performance athletes (60.7±7.5 versus 48.6±6.3 
g/m2; P<0.001); however, extracellular mass remained con-
stant (16.3±2.2 versus 15.3±2.2 g/m2; P=0.20; Figure 1). 
Myocardial ECV and native T1 in athletes were lower than 
in untrained controls (22.5±2.6% versus 24.5±2.2%, P=0.02; 
1178±32 versus 1202±33 ms, P=0.02). Although both the cel-
lular and extracellular masses were higher in athletes than in 
controls (15.8±2.2 versus 13.6±1.7, P<0.001; 55.1±9.2 versus 
42.3±5.7, P<0.001), the relative expansion of the cellular 
compartment was greater than the increase seen of the extra-
cellular compartment (130% and 116%, respectively).
Chamber Remodeling in High-Performance and 
Low-Performance Athletes
Typical findings may be seen in Figure 2, and full CMR data 
are given in Table 3. Both left ventricular mass index and left 
ventricular end-diastolic volume index differed significantly 
between athletes and untrained controls and between athletic 
groups (P<0.001 for all; Figure 2). Significant correlations 
were observed between cardiac chamber remodeling and 
V̇O2max: both left ventricular mass index and left ventricular 
end-diastolic volume index correlated significantly with each 
other (r=0.71, P<0.001) and with V̇O2max (r=0.55, P=0.002 
and r=0.45, P=0.01, respectively; Figure 3). In athletes, 
CMR measures of tissue composition (ECV and partition 
coefficient) differed between athletic groups and correlated 
significantly with V̇O2max: ECV r=−0.53, P=0.003; partition 
coefficient r=−0.41, P=0.02. Native T1 did not differ between 
athletic groups (low versus high performance; 1185±36 versus 
1171±28 ms; P=0.26). LGE was seen in one athlete only (3%) 
and was in a typical myocarditis pattern. A significant inverse 
Figure 2. Typical cardiac magnetic resonance 
(CMR) appearances in low-performance and 
high-performance athletes. Left column shows an 
athlete with a V̇O2max of 50 mL/kg per in, and right 
column shows a high-performance athlete with a 
V̇O2max of 75 mL/kg per min. A and D, Short-axis 
images of left and right ventricle. B and E, extra-
cellular volume (ECV) color maps showing lower 
ECV in the high performance athletes throughout 
the myocardium. C and F, Pie charts scaled to 
overall indexed LV mass displaying the relative 
indexed masses of the cellular and extracellular 
compartments (not short axis images). ECMI 
indicates indexed extracellular mass; and ICMI, 
indexed intracellular mass.
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correlation was seen between ECV and left ventricular mass 
index (r=−0.44, P=0.02; Figure 3).
Discussion
This study shows for the first time that LV hypertrophy in AH 
occurs as a consequence of differences in the relative compo-
sition of myocardium and that athletic hypertrophy is driven 
by an expansion of the cellular compartment with a relative 
decrease of the extracellular compartment. Furthermore, we 
have provided evidence of a potential relationship between 
increasing fitness and expansion of the cellular compartment. 
This finding provides novel insight into the physiological 
change underpinning the poorly understood phenomenon of 
athletic LVH. We have further demonstrated that the extent of 
cellular volume expansion is linearly related to aerobic capac-
ity in this cohort of endurance athletes.
Mechanism of Myocardial Adaption and Remodeling
Cardiovascular adaptation occurs in response to hemody-
namic challenge and prolonged endurance training and even 
in previously untrained individuals leads to marked changes in 
cardiac geometry.18 It has been shown in previous longitudinal 
studies that early adaption is characterized by an increase in 
LV mass and as a consequence change in LV mass:volume 
ratio, later followed by LV dilation, normalization of the ratio, 
and eccentric hypertrophy.18 LV geometry and particularly LV 
mass have previously been shown to be related to V̇O2max.19–21
CMR has provided new insights into the mechanisms 
that underpin cardiac remodeling with exercise training. The 
multiparametric assessment of the human heart and high 
reproducibility provided by the technique allow both accu-
rate functional and anatomic assessment.22–24 Native T1 and 
ECV measurement are robust and validated techniques for 
tissue characterization,25 and the correlation of ECV in par-
ticular with histological tissue specimens is excellent,22,23,26 
though has not previously been applied to athletes with known 
V̇O2max. ECV increases in myocardial fibrosis, edema, and 
expansion of the extracellular space, with subsequent relative 
decrease in myocyte mass.27 Conversely, an expanded cellular 
mass reduces ECV as the distribution volume for conventional 
extracellular contrast agents is reduced.
In this study, we have demonstrated that indexed LV mass 
is correlated with aerobic capacity and that indexed LV mass 
and ECV are inversely related. Participants with a higher 
V̇O2max had a similar extracellular mass as those with a lower 
V̇O2max, but a significantly higher intracellular mass.
These data allow postulation of the mechanism underlying 
the development of AH that is consistent with known concepts: 
Table 3. Cardiac Magnetic Resonance Findings
Untrained 
Individuals (n=20)
All Athletes 
(n=30) P Value
Low Performance 
(n=14)
High Performance 
(n=16) P Value
LVEDV, mL 195.1±26.0 229.7±30.7 <0.001 222.0±29.3 236.4±31.4 0.21
LVEDVi, mL/m2 98.6±12.3 117.7±15.1 <0.001 110.5±13.9 124.0±13.5 0.01
LVEDVi, LBM 37.5±10.4 45.9±6.0 <0.001 43.9±5.0 47.8±6.3 0.07
LV SV, mL 109.5±15.2 128.1±19.1 <0.001 123.4±17.1 132.2±20.3 0.21
LVEF, % 56.4±5.2 55.8±4.8 0.73 55.7±5.0 55.9±4.7 0.93
LV mass, g 109.2±16.3 138.4±21.3 <0.001 128.6±17.3 146.9±21.2 0.02
LVMi, g/m2 55.9±6.7 70.9±10.6 <0.001 63.9±7.5 77.0±9.2 <0.001
  Extracellular, g/m2 13.6±1.7 15.8±2.2 <0.001 15.3±2.2 16.3±2.2 0.20
  Cellular, g/m2 42.3±5.7 55.1±9.2 <0.001 48.6±6.3 60.7±7.5 <0.001
LVMi, LBM 20.5±5.9 27.8±4.6 <0.001 25.5±4.0 30.0±4.3 0.01
  Extracellular, LBM 4.9±1.5 6.2±0.9 0.001 6.1±1.0 6.3±0.9 0.59
  Cellular, LBM 15.6±4.6 21.6±3.9 <0.001 19.5±3.3 23.4±3.5 0.004
  LV volume:mass ratio 0.55±0.07 0.60±0.06 0.01 0.58±0.08 0.62±0.05 0.11
RVEDV, mL 218.7±30.5 236.7±36.8 0.15
RVEDVi, mL/m2 108.5±12.4 124.1±15.9 0.01
RVEDVi, LBM 43.2±5.2 47.8±7.0 0.047
RVEF, % 54.2±4.7 53.9±6.6 0.88
Tissue characterization
  LGE* 0 1 0.48 1 0 0.34
  Native T1 1202±33 1178±32 0.02 1185±36 1171±28 0.26
  Partition coefficient 0.45±0.5 0.41±0.05 0.03 0.44±0.05 0.39±0.03 0.01
  ECV, % 24.5±2.2 22.5±2.6 0.02 24.0±2.7 21.2±1.9 0.003
ECV indicates extracellular volume; LBM, lean body mass; LGE, late gadolinium enhancement; LV, left ventricle; LVEDV, LV end-
diastolic volume; LVEDVi, LV end-diastolic volume index; LVEF, left ventricular ejection fraction; LVMi, left ventricular mass index; 
RVEF, right ventricular ejection fraction; RVEDV, right ventricular end-diastolic volume; RVEDVi, right ventricular end-diastolic volume 
index; and SV, stroke volume.
*LGE seen in myocarditis pattern
 at University of Leeds on May 24, 2016http://circimaging.ahajournals.org/Downloaded from 
6  McDiarmid et al  Athletic LVH Is Secondary to Myocyte Hypertrophy 
After rapid division in fetal life, cardiac myocytes are terminally 
differentiated shortly after delivery. As a result, any increase in 
overall myocardial mass is secondary to myocyte hypertrophy 
or extracellular matrix expansion rather than cell hyperplasia.28 
CMR allows in vivo quantification of the 2 tissue compart-
ments, and our data show that in AH, the overall extracellular 
compartment volume is similar to previously reported normal 
ranges,29 although there is marked cellular expansion.
Important differential diagnoses of AH include dilated 
cardiomyopathy (DCM) and hypertrophic cardiomyopathy 
(HCM), which may both display increased LV mass or left 
ventricular end-diastolic volume. The role of CMR in the 
detection of these myocardial diseases is established, and both 
DCM and HCM display characteristic morphological abnor-
malities on CMR. At a microscopic level, HCM is character-
ized by myocyte disarray and interstitial fibrosis30 and, thus, 
higher ECV. LGE CMR allows detection of focal replacement 
fibrosis and infarction in both HCM31 and DCM32; however, 
diffuse processes are poorly detected with this technique. T1 
mapping and ECV measurement have shown expansion of 
the extracellular space in HCM, occurring in both hypertro-
phic23,29 and nonhypertrophic segments, as well as in DCM.33,34 
Our observation that hypertrophy in AH is cellular without, or 
with relatively less, ECV expansion suggests that T1 mapping 
Figure 3. Relationship between exercise capacity and left ventricular (LV) remodeling and remodeling and tissue composition (R and 
P values determined with Spearman correlation coefficient for all). A, LVEDVi and VO2max, r=0.45, P=0.01; B, LVMi and VO2max, r=0.55, 
P=0.002; C, extracellular volume and VO2max, r=−0.53, P=0.003; D, significant inverse relationship between extracellular volume (ECV) 
and indexed LV mass (r=−0.44, P=0.02). LVEDVi indicates LV end-diastolic volume index; and LVMi, left ventricular mass index.
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CMR may be used to distinguish between athletic LV adapta-
tion and pathological hypertrophy or remodeling.
Both side-by-side sarcomere addition in concentric remod-
eling and end-to-end addition in eccentric remodeling result 
in myocardial hypertrophy,35 with an increase of muscle mass 
without increase in myocyte number.36 In this study, conducted 
without tissue biopsy, we are unable to determine the intracellu-
lar sarcomere arrangement; however, other CMR techniques that 
allow myocyte size to be quantified, as investigated by Coelho-
Filho et al,37 may allow this to be determined in the future.
LGE and Myocardial Scar
LGE has previously been demonstrated in ≤13% of elite38 and 
50% of veteran athletes.39 In this cohort of athletes, LGE was 
seen in only 3% (n=1). This difference may be as a conse-
quence of the relatively young age of athletes studied.
Remodeling and Relationship With Performance
The relationship between aerobic capacity and LV remodel-
ing is known.19,20 In this study, we have demonstrated that left 
ventricular end-diastolic volume index and left ventricular 
mass index correlate with V̇O2max, confirming that the degree 
of remodeling is related to fitness, and our data are consistent 
with the literature.
Limitations
There was relatively little diversity in the range of athletic dis-
cipline pursued; however, this has previously been shown not 
to affect the phenotype of cardiac remodeling.40 Native T1 dif-
fered significantly between athletes and controls, but not athletic 
groups. Native T1 is increased in myocardial edema and inflam-
mation, but also in increased extracelluar volume; consequently, 
these findings are consistent with ECV in this study. The rea-
son for a lack of difference between athletic groups is not clear, 
however, and merits further study. Furthermore, the assumptions 
made regarding the mode of myocardial hypertrophy in AH in 
this study have not been validated by histological sample. We 
have not studied female athletes in this study in order to have a 
homogenous study sample, but it is possible that athletic adap-
tion differs compared with men. Finally, the participants were 
all of white origin, and this study should be repeated in a range 
of ethnic origins in an effort to understand AH in all athletes 
because risk and remodeling may differ between ethnicities.41
Conclusions
Cardiac remodeling and LVH in AH occurs as a consequence 
of greater myocyte mass, with an associated relative decrease 
of the extracellular space. This is unlike HCM or DCM, where 
CMR tissue characterization detects marked expansion of 
the extracellular space, in the presence or absence of LVH. 
Athletic remodeling, both on a macroscopic and microscopic 
level, is associated with the degree of aerobic capacity. ECV 
quantification with CMR may have a future role in differen-
tiating AH from change secondary to cardiomyopathy, espe-
cially HCM, and warrants further study.
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CLINICAL PERSPECTIVE
The need for reliable methods to differentiate physiological and pathological left ventricular hypertrophy are brought into 
focus by the rare but prominent cases of sudden death in elite athletes and the young. However, the myocardial changes that 
occur in an athlete’s heart are poorly understood, and current assessment is dependent on a constellation of findings, but may 
be limited when significant abnormalities are not present. Consequently, differentiating between physiological and pathologi-
cal left ventricular hypertrophy can be difficult in borderline cases. Cardiac magnetic resonance provides highly reproducible 
assessment of cardiac structure and function. The developing field of cardiac magnetic resonance T1 mapping is now allowing 
insights into tissue composition with quantification of the extracellular space, not previously possible with contrast-enhanced 
cardiac magnetic resonance. In this study, we have used T1 mapping to demonstrate that increased left ventricular mass in 
physiological hypertrophy is predominantly because of expansion of the cellular, rather than the extracellular compartment. 
Furthermore, the degree of myocardial adaptation and cellular expansion is related to aerobic capacity, with fitter individuals 
displaying more expansion of the cellular compartment. Relatively lower extracellular volume is a crucial difference from 
many cardiomyopathies that are characterized by myocardial fibrosis and expansion of the extracellular space. The relatively 
lower extracellular volume in physiological left ventricular hypertrophy may provide a foundation for future studies to test 
whether extracellular volume quantification can differentiate the underlying nature of left ventricular hypertrophy.
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